ghk cu dosage subq dosing chart for skin ghk-cu recommendations human use ghk-cu peptide injection ghk-cu dosage subcutaneous ghk cu

The FDA placed it in 503A Category 2 ("may present significant safety risks") in 2023, effectively barring compounding pharmacies from using it, then removed it from that category in April 2026 after nominators withdrew their submission, without adding it to the approved Category 1 compounding list

Reduced joint pain and improved mobility

Also, one less metabolic step is needed for the conversion of hydroxocobalamin than cyanocobalamin

Preclinical studies suggest it can protect nerve cells (neuroprotective effects)

The debate often boils down to two campslocalized versus systemic application

An earlier landmark study by Staresinic et al